TRC 041266
Alternative Names: TRC041266Latest Information Update: 06 Jan 2023
At a glance
- Originator Torrent Pharmaceuticals
- Class Decanoic acids; Heart failure therapies; Hydrazines; Pyridinium compounds; Small molecules; Sulfones; Thiophenes
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 23 Dec 2022 Torrent Pharmaceuticals withdraws a phase III trial in Heart failure (NCT04507347)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in India (PO, Powder)
- 11 Aug 2020 Torrent Pharmaceuticals plans a phase III trial for Heart failure (In adults, In elderly) (PO) in June 2021 (NCT04507347)